Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Amneal and Shilpa Gain FDA Approval for BORUZU™, Ready-to-Use Bortezomib
Details : Bortezomib injection is a proteasome inhibitor approved for treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.
Brand Name : Boruzu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2024
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Completes Phase 1 Trial of Human Albumin as First in India
Details : sRbumin (recombinant human albumin) is a synthetic form of human serum albumin protein, which is currently being evaluated for the treatment of accidents, burns, and surgeries.
Brand Name : sRbumin
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 28, 2024
Lead Product(s) : Albumin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Launches Pemetrexed Injection
Details : Pemrydi (pemetrexed) is the first ready-to-use formulation approved for commercialization in the US market. It is indicated for patients suffering from non-small cell lung cancer.
Brand Name : Pemrydi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2024
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Amneal Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Gets Europe Approval for Varenicline Tablets, 0.5mg and 1mg
Details : Varenicline is a nAChRα4&β2 (Neuronal acetylcholine receptor; alpha4/beta2) agonist, small molecule drug. It is approved for the treatment of smoking cessation.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Curcuma Longa,Glycerine,Propolis
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Launches 'Oraal’ for Treatment of Oral Mucositis
Details : ORAAL, an oral spray with a naturally derived formulation, which is indicated for the treatment of oral mucositis. The composition of ORAAL is protected by a granted patent in India until November 2033.
Brand Name : Oraal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Lead Product(s) : Curcuma Longa,Glycerine,Propolis
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Receives UKMHRA Approval for Mouth-dissolving Strips to Treat Illnesses
Details : Betahistine dihydrochloride is an antivertigo agent, which is act as the histamine receptor inhibitor, which is indicated for the reduction of recurrent vertigo episodes associated with Meniere's disease in patients 18 years old and above.
Brand Name : Betahistine Dihydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 03, 2023
Lead Product(s) : Betahistine Dihydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lenvatinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Launches Lenvatinib Capsules in India Under the Brand Name Lenshil
Details : Lenshil (lenvatinib mesylate), an oral receptor tyrosine kinase inhibitor, launched in India, for the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer.
Brand Name : Lenshil
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2023
Lead Product(s) : Lenvatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apremilast
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shilpa Medicare Gets Tentative American Health Regulator Nod for Apremilast Tablets
Details : The company has received tentative approval from US Food and Drug Administration for its abbreviated new drug application (ANDA) Apremilast tablets in the strengths of 10 mg, 20 mg, and 30 mg, Shilpa Medicare said in a regulatory filing.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 05, 2021
Lead Product(s) : Apremilast
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?